SCR&Tox research programme is organised in six workpackages, four of them are scientific, the fifth is in charge of training and dissemination, including workshops to regulatory bodies and the sixth workpackage that is involved in the SCR&Tox project management.
Johan Hyllner is the leader for the biological resources workpackage; his company, Cellartis, is a major industrial player worldwide with ten years expertise in the production of human pluripotent stem cell lines for industrial use. Work package 1 will provide the necessary biological resources by amplifying and banking undifferentiated cells and by supplying protocols and production of differentiated cells, aiming specifically at :
Catharina Ellerström is the leader for the technological resources workpackage; representing Cellectis Stem Cells a Cellectis business unit that combines two Cellectis Group companies dedicated to stem cell technology. These are Ectycell, based at the Evry Genopole (France), and Cellartis, based in Gothenburg (Sweden), which was acquired by Cellectis in October 2011.
The goal of the "Cellectis stem cells" Business Unit is to speed up the development of stem cell technology and in particular to find a robust and reproducible way of controlling stem cell production and differentiation, notably through the sharing of knowledge and expertise developed by the two companies, with a view to becoming a major, long-term and stable industrial player in the global marketplace.
Cellectis is a key player worldwide with ten years of expertise in genome engineering and delivery of engineered cells to the industry. Work Package 2 will explore cell functions, optimise cells for assays and prepare cells for high throughput screening platforms, by:
Susanne Bremer-Hoffmann is leader for the assay development workpackage. She has been responsible for more than 12 years at ECVAM for exploring and validating cell-based assays for toxicology, in particular using embryonic stem cells and, as such, has participated to the validation of the EST, the only test based on ES cells to-date which has been approved by regulatory bodies for reproductive toxicology testing. Workpackage 3 main objectives are the definition, implementation, normalisation and validation of assays by:
Roy Forster is leader for the industrial-scale prototypes workpackage; his company, CIT, is one important CRO in the field of toxicology testing with major interest in the development of new approaches for testing cosmetic ingredients and pharmaceutical compounds. Work package 4 main objectives are: